- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Jamie Peck, Rosetta
Independence equals creativity, and solutions
Global holding companies are, in reality, nothing more than loose confederations of independent agencies, each with their own profit and loss statements (P&Ls) and profit goals. This can create multiple layers of unnecessary bureaucracy and overhead, actually resulting in increased cost to the client.
Jamie Peck
In a word, independence gives birth to creativity. Rosetta's point of view is that independent alliances, while sometimes hard to centrally manage, are the most effective way to serve our global clients creatively. For Allergan EMEA, Rosetta has acted as a sole provider of all digital solutions in 11 countries. This has resulted in several award-winning digital solutions, all managed centrally from the US.
By recognizing the inverse dynamic of emerging media in emerging regions, HC marketers can leverage the power of an entire arsenal of tools. Outside of the US, the Web is merely a portal or gateway for the patient and provider to access a myriad of other digitally enabled media outlets. By accessing these other channels (mobile, social, gaming, etc.), we are able to meet all of the targets' needs—emotional, educational, and value based—through the devices they rely on every day.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
